Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRICKLE1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRICKLE1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRICKLE1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0035567 | Lung | AIS | non-canonical Wnt signaling pathway | 16/1849 | 72/18723 | 1.50e-03 | 1.81e-02 | 16 |
GO:190332211 | Lung | AIS | positive regulation of protein modification by small protein conjugation or removal | 25/1849 | 138/18723 | 2.05e-03 | 2.26e-02 | 25 |
GO:007217511 | Lung | AIS | epithelial tube formation | 24/1849 | 132/18723 | 2.37e-03 | 2.48e-02 | 24 |
GO:003139811 | Lung | AIS | positive regulation of protein ubiquitination | 22/1849 | 119/18723 | 2.85e-03 | 2.84e-02 | 22 |
GO:0090090 | Lung | AIS | negative regulation of canonical Wnt signaling pathway | 24/1849 | 137/18723 | 3.91e-03 | 3.59e-02 | 24 |
GO:0010498113 | Thyroid | PTC | proteasomal protein catabolic process | 297/5968 | 490/18723 | 4.58e-40 | 9.63e-37 | 297 |
GO:0043161113 | Thyroid | PTC | proteasome-mediated ubiquitin-dependent protein catabolic process | 254/5968 | 412/18723 | 3.91e-36 | 4.54e-33 | 254 |
GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
GO:0042176113 | Thyroid | PTC | regulation of protein catabolic process | 231/5968 | 391/18723 | 4.76e-29 | 2.14e-26 | 231 |
GO:0072594112 | Thyroid | PTC | establishment of protein localization to organelle | 244/5968 | 422/18723 | 1.18e-28 | 4.97e-26 | 244 |
GO:1903362113 | Thyroid | PTC | regulation of cellular protein catabolic process | 162/5968 | 255/18723 | 1.62e-25 | 5.12e-23 | 162 |
GO:0006913112 | Thyroid | PTC | nucleocytoplasmic transport | 181/5968 | 301/18723 | 2.93e-24 | 7.69e-22 | 181 |
GO:0051169112 | Thyroid | PTC | nuclear transport | 181/5968 | 301/18723 | 2.93e-24 | 7.69e-22 | 181 |
GO:1903050113 | Thyroid | PTC | regulation of proteolysis involved in cellular protein catabolic process | 140/5968 | 221/18723 | 4.63e-22 | 1.01e-19 | 140 |
GO:0034504111 | Thyroid | PTC | protein localization to nucleus | 170/5968 | 290/18723 | 3.34e-21 | 6.38e-19 | 170 |
GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
GO:0045732113 | Thyroid | PTC | positive regulation of protein catabolic process | 142/5968 | 231/18723 | 1.43e-20 | 2.38e-18 | 142 |
GO:2000058113 | Thyroid | PTC | regulation of ubiquitin-dependent protein catabolic process | 110/5968 | 164/18723 | 1.83e-20 | 2.97e-18 | 110 |
GO:0061136113 | Thyroid | PTC | regulation of proteasomal protein catabolic process | 121/5968 | 187/18723 | 2.25e-20 | 3.37e-18 | 121 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRICKLE1 | SNV | Missense_Mutation | rs376845777 | c.805G>A | p.Gly269Arg | p.G269R | Q96MT3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PRICKLE1 | SNV | Missense_Mutation | | c.2460N>C | p.Lys820Asn | p.K820N | Q96MT3 | protein_coding | deleterious(0) | benign(0.368) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRICKLE1 | insertion | In_Frame_Ins | novel | c.1717_1718insTGATGGAAAATTCAACTTTTTTTGATTTTTTTT | p.Asp573delinsValMetGluAsnSerThrPhePheAspPhePheTyr | p.D573delinsVMENSTFFDFFY | Q96MT3 | protein_coding | | | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PRICKLE1 | insertion | Frame_Shift_Ins | novel | c.1748_1749insAC | p.Asn584ArgfsTer13 | p.N584Rfs*13 | Q96MT3 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRICKLE1 | insertion | In_Frame_Ins | novel | c.1747_1748insGGACAACCAATCCCTCAACCCCGGCCACAGAGATTTGCC | p.Thr582_Leu583insTrpThrThrAsnProSerThrProAlaThrGluIleCys | p.T582_L583insWTTNPSTPATEIC | Q96MT3 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRICKLE1 | SNV | Missense_Mutation | novel | c.1076N>G | p.Lys359Arg | p.K359R | Q96MT3 | protein_coding | tolerated(0.35) | benign(0.012) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRICKLE1 | SNV | Missense_Mutation | novel | c.646N>A | p.Phe216Ile | p.F216I | Q96MT3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRICKLE1 | SNV | Missense_Mutation | rs765119777 | c.434N>T | p.Ala145Val | p.A145V | Q96MT3 | protein_coding | deleterious(0.04) | possibly_damaging(0.894) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
PRICKLE1 | SNV | Missense_Mutation | | c.2078N>A | p.Arg693Lys | p.R693K | Q96MT3 | protein_coding | tolerated(0.08) | benign(0) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRICKLE1 | SNV | Missense_Mutation | novel | c.1936N>A | p.Glu646Lys | p.E646K | Q96MT3 | protein_coding | tolerated(0.76) | benign(0.001) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |